Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus FLUDEOXYGLUCOSE F18.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus FLUDEOXYGLUCOSE F18.
CIS-MDP vs FLUDEOXYGLUCOSE F18
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical